Skip to main content
  • Extended Clopidogrel Monotherapy Is Superior to DAPT in Bi-Risk ACS Patients: OPT-BIRISK

    An extended 9-month clopidogrel monotherapy regimen was superior to dual antiplatelet therapy (DAPT) in reducing clinically relevant bleeding without increasing ischemic events among acute coronary syndrome (ACS) patients at both high bleeding and ischemic risks (bi-risk) who had already completed 9-12 months of DAPT after drug-eluting stent (DES) implantation, randomized controlled trial data suggest.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details